Recent developments include a significant stock price increase in early April 2026 linked to acquisition interest by Biogen, ongoing market activity in the biotech sector, and earnings previews indicating expected declines for Q4 2025.

• Apellis Pharmaceuticals' stock price increased 135.4% in early April 2026 amid acquisition interest by Biogen [N4].
• Biogen's Q1 earnings report discussed new launches and challenges in its multiple sclerosis franchise, relevant to the merger context [N1].
• The SPDR S&P Biotech ETF experienced significant inflows in April 2026, reflecting sector interest [N2].
• Earnings previews in February 2026 indicated expected declines for Apellis' Q4 earnings [N6].
• Analysts highlighted Apellis among drug/biotech stocks likely to outperform Q4 earnings estimates in early February 2026 [N7].
• Apellis shares surged 5.8% in late January 2026, indicating market interest [N8].

The company has demonstrated operational progress with positive net income and strong liquidity as of the end of 2025. The announced merger agreement with Biogen reflects strategic value recognition by a major industry player. Apellis' product portfolio and collaborations provide multiple revenue streams and potential for growth in immunology and rare diseases. The experienced leadership team and structured governance support continued development and commercialization efforts.

Risks include uncertainties related to the completion and integration of the merger with Biogen, potential regulatory hurdles, and the possibility that anticipated benefits from the merger may not materialize. The biotechnology industry faces competitive pressures, regulatory scrutiny, and market volatility. The company’s financial performance and stock price have shown volatility, and reliance on a limited product portfolio and collaborations may pose concentration risks. Legal and operational risks related to the merger and ongoing business activities are also present.

Apellis Pharmaceuticals' moat is supported by its proprietary therapies in immunology and rare diseases, including SYFOVRE and EMPAVELI, which have regulatory approvals and commercial presence. The company's strategic collaborations, such as the Royalty Buy-Down Agreement with Sobi, and its pipeline development contribute to competitive positioning. The experienced management team and board with deep industry knowledge enhance execution capabilities. However, the biotechnology sector is competitive with risks from regulatory, market, and integration challenges, especially in light of the pending merger with Biogen.

• Merger Completion and Integration Risks: The pending merger with Biogen involves regulatory approvals, stockholder acceptance, and integration challenges that could affect business operations and financial results.
• Regulatory and Market Risks: The biotechnology sector is subject to regulatory scrutiny, pricing pressures, and competition from established and emerging companies, which may impact product commercialization and revenues.
• Operational and Financial Risks: Volatility in financial performance, reliance on key products and collaborations, and potential legal proceedings related to the merger or business activities may adversely affect the company.

• Apellis Pharmaceuticals, Inc. is a Delaware corporation with principal executive offices in Waltham, MA.
• The company is publicly traded on the Nasdaq Global Select Market under the ticker APLS.
• As of April 21, 2026, there were 128,021,277 shares outstanding.
• The company has a board of directors divided into three classes with staggered three-year terms, including experienced members with backgrounds in pharmaceutical research, commercial leadership, venture capital, and biotechnology.
• Cedric Francois, M.D., Ph.D., is the co-founder, President, and Chief Executive Officer since 2009.
• The company has entered into a merger agreement with Biogen Inc. announced on March 31, 2026, involving a tender offer at $41.00 per share plus contingent value rights.
• Apellis has a Royalty Buy-Down Agreement with Swedish Orphan Biovitrum AB (Sobi) effective July 1, 2025, involving upfront and milestone payments and royalty adjustments.
• The company reported financial figures for the fiscal year ended December 31, 2025, including cash and equivalents of $466.2 million, current assets of $1.015 billion, current liabilities of $323.6 million, net income of $22.4 million, basic EPS of $0.18, and diluted EPS of $0.20.
• Liquidity ratios as of December 31, 2025, include a current ratio of 3.14 and a cash ratio of 1.83, indicating strong short-term liquidity.
• The company has adopted Rule 10b5-1 trading plans for certain officers, including the CEO and CFO, for the sale of shares.
• Recent news highlights include a 135.4% stock price increase in early April 2026, linked to acquisition interest by Biogen and other market activities.
• Apellis' product portfolio includes SYFOVRE and EMPAVELI, with reported U.S. net product revenues for Q4 and full year 2025 announced in January 2026.
• The company faces risks related to the merger process with Biogen, including regulatory approvals, integration challenges, and potential litigation.
• Apellis' executive compensation program is designed to align with pay-for-performance principles and includes fixed salary, annual cash incentives, and long-term incentive plans.
• The company operates in the biotechnology and pharmaceutical sector with a focus on immunology and rare diseases.
• Apellis' board and management have extensive experience in pharmaceutical development, commercialization, and investment.